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Introduction: There is little information on the outcome of HIV1
pts with MM undergoing myeloablative chemotherapy with ASCT
Patients and Methods: 3 male HIV 1 pts with MM underwent
ASCT between June 2005 and December 2009. Median age of 46
years (43-66 years). All received multiagent chemotherapy including
bortezomib, dexamethasone, thalidomide, cisplatin, adriamycin, cy-
closphosphamise, etoposide (VDT-PACE) and granulocyte colony
stimulating factor (GCSF) for mobilization of hemopoeitic periph-
eral stem cells (HPC). HAART was held during VDT-PACE and
HPC. All collected adequate CD 341 cells/kg (median 25.4x106
cells/kg (17.4-31.9 x106 cells/kg)) for tandem transplant. HAART
was resumed during myeloablative chemotherapy and ASCT. De-
mographics, HIV viral load (VL), myeloma and HIV outcomes
were reviewed.
Results: Median absolute CD4 cell count prior to ASCT was 64
cells/mL (43-264 cells) and median HIV viral load (VL) was 2070
copies/mL (153-9550 copies/mL). Conditioning regimens were
melphalan 200 mg/m2 (2 pts) and carmustine, etoposide, adriamy-
cin, melphalan (BEAM, 1 pt). Median viable CD341 cells/kg in-
fused was 2.96  106/kg (range 2.58-3.26  106/kg). Median
days to neutrophil and platelet engraftment were respectively 11
(range 7-14) and 18 (range 16-19) days. Treatment-related compli-
cations included colitis (3 pts, C. difficile in 1), gram negative sepsis
(1 pt) and pulmonary aspergillosis (1 pt). Following ASCT, all pts
responded, with 2 achieving complete remission which was main-
tained for 1 year (1 pt) and 2 years (1 pt). One pt died 2 months
after transplant after refusing more treatment (cause of death un-
clear). The median CD4 count 1-3 months after transplantation
was 94 cells/uL (range 19-105) and median HIV VL was 1510 cop-
ies/mL (range 687-9270). The HIV VL was undetectable at 1 year
in 2 pts.
Conclusion:Myeloablative chemotherapy with ASCT can be safely
applied to HIV 1 pts with MM receiving HAART with good
outcome at 1-2 years after ASCT.275
AUTOLOGOUS STEM CELL TRANSPLANT (SCT) IN PATIENTS WITH
MULTIPLE MYELOMA (MM) OVER THE AGE OF 65 YEARS IS FEASIBLE
AND SAFE
Jagdeesh, D., Nath, R. UMassMemorial Medical Center,Worcester,MA;
Saint Vincent Medical Center, Worcester, MA
Background: Autologous SCT improves response rates and survival
in all newly diagnosed transplant eligible patients withMM. Patients
older than 65 years of age are frequently considered ineligible for this
procedure.
Materials and Methods: Retrospective analysis was performed on
all patients with MM over the age of 65 years who underwent au-
tologous SCT at UMass Memorial medical center since January
2003.
Results: 33 autologous SCT were performed on 27 patients with
MM over the age of 65 years. Thirteen (39%) SCT were performed
in patients older than 70 years. The median age at SCT was 68 years
(range 65-77).24 SCT were performed in males and 10 SCT were
performed in females.Myeloma subtype was IgG k 14 (52%); IgA
k 6 (22%); IgG l 4 (15%) and light chain myeloma in 3 (11%). Me-
dian time from diagnosis to transplant was 11 months (range 4-143).
In 13(48%) instances patients had more $ 3 therapies prior to their
SCT. 10(29%) of the SCT were 2nd transplants and there was one
instance of 3rd SCT. Preparative regimen was melphalan 100-
200mg/m2.Median time for neutrophil recovery was 11 days (range
9-12) and platelet recovery was 18 days (range 10-26). No patient
died within 100 days post transplant.1 year mortality was 10% (3/
31). The survival of patients $ 70 years was similar to those # 70
years. 7/15 (46%) of the patients transplanted beyond 5 years are still
alive.
Conclusion: Autologous SCT is feasible and a safe treatment mo-
dality for MM patients older than 65 years of age. This treatment
modality needs to be evaluated further in prospective randomized
clinical trials.276
CYTOGENETICS AND FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
CHANGES BEFORE AND AFTER THERAPY AND TRANSPLANT IN PATIENTS
WITH MULTIPLE MYELOMA
Frahan, S., Mckinnon, R., Fortney, C., Janakiraman, N. Henry Ford
Hospital, Detroit, MI
Background: Multiple Myeloma (MM) has a very heterogeneous
prognosis. Many studies suggested that specific chromosomal
changes are of prognostic significance in patients with MM. Poor
risk include t(4;14), t(14;16),t(14;20), deletion p53, deletion 13 and
hypodiploidy. Changes of genetics during course of treatment and
outcome are not well studied. 132 cases of Multiple Myeloma trans-
plants were retrospectively reviewed from January 1st, 2000 to Au-
gust 1st, 2010. We looked at cytogenetics and fluorescence in situ
hybridization (FISH) before starting treatment, before and after
transplant.
Results: Out of 132 patients, 84.1% had Auto stem cell transplant
and 24 (15.9%) had Allo stem cell transplant. Mean age at diagnosis
was 54.6 (24-76). Patients with stage I-II were 28.2%, the rest had
stage III. 35 patients had monosomy or deletions of chromosome
13 (ch13) detected by FISH at diagnosis or any point during their
treatment. Of these, 11 patients had ch13 abnormality detected by
FISH during the course of treatment not at time of diagnosis. 3
(2.3%) patients had abnormalities of ch13 detected by cytogenetics.
11 patients had p53 deletion. It was detected in 8 patients before
transplant and was still detectable in 3 out of those 8 patients during
therapy and transplant. Another 3 patient had p53 deletion detected
only after transplant and was not detected before. 11 patients had
complex genetics at around time of diagnosis and 25 patients had
complex genetics detected just before and after time of transplant.
One patient had t(4;14). By time of analysis, there were 57 (43.2%)
death and 75 (56.8%) patients who were still alive. 80 (60.6%) pa-
tients had a relapse at one point. Median time to relapse (days) was
945 (251-9848). After dividing patients with high risk genetics at
any point during there treatment before or after transplant .and
standard risk, which includes everybody else, we found a significant
association between risk and death (p 5 0.001).
Conclusion: In this small group of 132 patients with MM who had
stem cell transplant in the last ten years from a single center we have
some data that may suggest high risk genetics detected at any point
during therapymay affect prognosis. This supports the need tomon-
itor genetics at diagnosis and during therapy. Since this is a small
group, further studies involving larger cohort of patients need to
be designed to confirm these results and study the effect of changes
of genetics during treatment of MM.277
SKELETAL CT SCAN IS MORE SENSITIVE THAN SKELETAL SURVEY
DURING THE PRE-TRANSPLANT EVALUATION FOR MULTIPLE MYELOMA
PATIENTS BUT HAS NO PROGNOSTIC SIGNIFICANCE
Moreb, J.S.1, Pettiford, L.1, Salejee, I.1, Bush, C.2 1University of Florida;
2University of Florida
Skeletal survey continues to be the gold standard radiologic
method for the detection of lytic lesions in multiple myeloma
(MM) patients. CT scans, MRI or PET scans have been used to eval-
uate specific symptoms. In our institution, we have used both skeletal
non-contrast CT scan and skeletal survey to evaluate for bone disease
during the pre-transplant evaluation of MM patients. Due to lack of
billing code for such test, the charges have been generated under the
code for CT scan of the abdomen or the spine. Our aim was to assess
the differences between the two modes of x-rays and to evaluate the
impact on progression –free (PFS) and overall survival (OS) after
stem cell transplant. We retrospectively reviewed the medical re-
cords of patients from our transplant registry that underwent stem
cell transplant (SCT) between January 2005 and December 2008.
Total of 154 patients were reviewed and 70 patients had the two
studies done during the pre-transplant evaluation. The following
data was collected: age, gender, stage of disease, albumin, b2-micro-
globulin, cytogenetics and FISH results, time to relapse, and time to
death. Patients were divided into two groups for comparison: those
who had differences between CT scan and skeletal survey findings
versus those who did not. The results show that CT scan had
more findings than the skeletal survey in 60% of the patients. These
Poster Session I S255findings included lytic lesions, pathological fractures or compression
fractures of vertebral bodies that were not seen well by the skeletal
survey. However, there were no significant differences in the median
PFS or OS between the two patient groups. There were total of 9 pa-
tients that had no bony lesions in either the survey or the CT scan
and their PFS and OS were not different either. We conclude that
CT scan of the skeleton is more sensitive in defining existing bony
lesions in MM patients at diagnosis, although these extra findings
may not have any impact on the PFS or OS of patients undergoing
SCT. The CT scan findings may have implications to palliative
and supportive care treatments for these patients.278
FEWER PULLS REQUIREDWHEN USING A POWERED BONEMARROWBI-
OPSY SYSTEM TO OBTAIN CORE SAMPLES IN THE MULTIPLE MYELOMA
PATIENTS POPULATION
Anaissie, E.J.1, Lorsbach, R.B.1, Johnson, K.D.1, Hill, M.W.2,
Philbeck, T.E.2 1University of Arkansas for Medical Sciences, Little
Rock, AR; 2Vidacare Corporation, Shavano Park, TX
Introduction: A study was conducted to compare a new powered
bone marrow sampling device to traditional manual bone marrow
sampling devices. The specific objectives of the study were to exam-
ine the number of passes required to obtain a satisfactory bone mar-
row core sample and measure the length of samples obtained from
each pull, using each device-type; and compare the results.
Methods: All patients had been diagnosed with multiple myeloma
and had undergone previous bone marrow biopsy procedures. Clini-
cians were already well experienced using the manual device, but had
only limited experiencewith the powered device. Following consent-
ing procedures and local anesthetic administration, 2 biopsy proce-
dures were performed unilaterally on each patient; one using the
traditional manual device and one using the powered device. The
manual device was a Jamshidi 11 gauge  4 inch needle (Cardinal
Health, Dublin, OH). The OnControl powered device included an
11 gauge, 102cm needleset (OnControl, Vidacare Corporation, Sha-
vano Park, TX). The device-type for the first procedure was alter-
nated from one patient to the next. Data collected included the
core specimen length obtained for analysis, and the number of pulls
required for a satisfactory specimen—defined by pathologists as
a core sample at least 1.0cm in length. An ‘‘ideal’’ specimen was de-
fined by pathologists as one with a length of $ 1.7cm. Pathology
graded specimens as Satisfactory, Unsatisfactory, or Limited. For
study purposes, up to 3 passes were allowed to obtain core speci-
mens. Results were compared between device-types and pull se-
quence. Data analysis, including descriptive statistics, t-tests, and
Chi-square analysis was performed using SPSS Statistics 19.0 soft-
ware (SPSS, Inc. Chicago, IL), with an alpha level of 0.05.
Results: Over a 30-day period, double biopsy procedures were per-
formed for 20 patients by 4 medical clinicians (1 nurse and 3 medical
assistants). See Table for specific results.Table 1. Study Results
Results by Device-Type Manual
Mean number of passes for procedure 1.95 ± 0.95
Core sample obtained on first pass 55%
Mean biopsy core length (mm) 1.11 ± 0.59
Ideal length core sample obtained
on first pass
20%
Pathology graded core sample
satisfactory or limited
85%
Results by Pull Sequence 1st
Mean number of passes for procedure 1.55 ± 0.89
Core sample obtained on first pass 65%
Mean biopsy core length (mm) 1.67 ± 0.57
Ideal length core sample obtained
on first pass
30%
Pathology graded core sample
satisfactory or limited
80%
†indicates statistical significanceConclusions: Study results suggest that, for multiple myeloma pa-
tients, the Powered bone marrow biopsy device may be preferable
to traditional Manual devices. This is due to the ability of operators
to consistently obtain ideal or adequate core biopsy specimens with
only one pass. Fewer passes means faster procedures and may result
in a reduction in pain to the patient, as well as less fatigue to the
clinician/operator.279
SUCCESSFUL AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWING A
COMBINED HEART-KIDNEY TRANSPLANTATION FOR AL AMYLOIDOSIS
William, B.M., Raichlin, E., Um, J.Y., Morris, M.C., Miles, C.D.,
Groggel, G.C., Faber, E.A. University of Nebraska Medical Center,
Omaha, NE
Background: Simultaneous cardiac and renal involvement is associ-
ated with a particularly poor prognosis in patients with AL amyloid-
osis. High-dose melphalan followed by autologous stem cell
transplantation (ASCT) offers the best chance for long-term survival
in patients with AL amyloidosis. Eligibility criteria for ASCT differ
between hematologic centers, because this treatment is associated
with high levels of mortality, which are increased by cardiac and/or
renal involvement. However, successful ASCT was reported after
cardiac and renal transplantation.
CaseReport:We report a case of a successful ASCT following com-
bined heart and kidney transplantation in a patient with systemic AL
amyloidosis. The recipient was a 61-year-old man with end-stage re-
nal failure associated with restrictive cardiomyopathy secondary to
AL amyloidosis. On presentation, cardiac biopsy showed cardiac am-
yloid involving the intramural arteries and interstitium and kidney
biopsy showed renal amyoid with lambda light chain deposition. Ini-
tial bone marrow biopsy showed a 40-50% cellular marrow with 4%
plasma cells and serum lambda light chains were elevated at 37.5 mg/
ml (5.7-26.3). One year after presentation, he underwent a successful
combined heart and kidney transplant. His post-transplant course
has been unremarkable except for ureteral leak that required surgical
revision. Immune suppression was maintained with tacrolimus and
mycophenolate mofetil. Four months after, he received 100 mg/
m2 melphalan on D-3 followed by ASCT. The infused stem cells
dose was 7.33  106/kg (which was half of what was collected). My-
cophenolate dose was reduced to allow engrafment and patient was
started on growth factors byD17. Immediate post-transplant course
was complicated by neutropenic fever secondary to streptococcus
viridans bacetermia which was successfully treated with. Patient
had successfully engrafted by D112 and was discharged from the
hospital by D117. One month after discharge of the hospital, he
continues to do well and didn’t require any blood product support.
Discussion: ASCT following combined heart and kidney transplant
is safe and feasible.We await to observe long-term outcomes though.Powered p-value
1.05 ± 0.22 <0.001†
97% <0.001†
1.60 ± 0.36 0.003†
55% 0.048†
85% 0.889
2nd p-value
1.45 ± 0.76 0.704
70% 0.710
1.77 ± 0.35 0.507
45% 0.257
90% 0.637
